Moreover, the recent success of the INDIGO clinical trial on <b>AG-881</b> (vorasidenib<sup>®</sup>), an aminotriazine-based mutated IDH1/2 inhibitor (IC<sub>50</sub> = 6 nM/12 nM), validated the need for noninvasive detection of mIDH1 in brain tumors. The gene discussed is IDH1; the disease is brain neoplasm.